Announcement Hemostemix Inc. is delighted to read out the bond letter of its plant for beginning with the first two cardiology practices via acquisition strategy, inspired by the Company’s intelligent commercialisation strategy and clinic roll-up. The intense practices of Dr Hector Rosario F...
Announcement TempraMed Technologies Ltd., a Canada-based leading company, has entered a particular exclusive commercial distribution partnership with Guri A.A.O. to sell and promote (market) TempraMed’s full product line throughout the Israeli retail market. This partnership deal represents ...
Announcement After the FDA approved Otsuka’s anti-APRIL antibody sibeprenlimab to alleviate the urine protein level in the IgA nephropathy patient group, this approved drug will be commercialised under the brand name ‘Voyxact’. This regulatory relief will make this drug the first...
Announcement FUJIFILM Healthcare Americas Corporation, a pioneering champion in enterprise and diagnostic imaging solutions, will be ramping up its current diagnostic imaging innovations in the South Hall at the 2025 Radiological Society of North America (RSNA) annual meeting (booth #3300), McCorm...
Announcement Pasithea Therapeutics Corp., a leading clinical-level biotechnology company establishing a next-generation macrocyclic MEK inhibitor, PAS-004, is delighted to announce that its PAS-004 study in ALS patients has been awarded a Hoffman ALS Clinical Trial Award from the ALS Association w...
Announcement Phio Pharmaceuticals Corp., a clinical-level siRNA biopharmaceutical company establishing a therapeutic game with its exclusive INTASYL® gene silencing technology to treat cancer, has completed its enrolment process in the Phase 1b clinical trial. It’s a clinical trial of IN...
Announcement Novartis’ intrathecal form of spinal muscular atrophy gene therapy, Zolgensma, received FDA approval. With this approval, Novartis will expand access to this therapy, reaching patients aged 2 years and older. Hearing this advantage from this approval, the Stanford Medicine profe...
Announcement Thermo Fisher Scientific Inc. declared that it has listed the pricing of the €2.1 billion offerings, estimated principal amount of the euro-denominated senior notes. This will be released by Thermo Fisher Scientific (Finance I) B.V., it’s a financial indirect wholly owned fi...
Announcement Bristol Myers Squibb proudly confirmed that they have officially received a European Commission’s approval stamp on Breyanzi® potential, a CD19-directed chimeric antigen receptor (CAR) T cell therapy. This therapy is for the treatment of adult patients group having refractory...
Announcement Eli Lilly and Company expressed its double excitement by confirming that it will be showcasing the new data from throughout its breast oncology portfolio and the robust pipeline at the San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas, December 9-12. These new updates ...
